<DOC>
	<DOC>NCT02546791</DOC>
	<brief_summary>This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days. The study will include 100 patients treated in different public centers in the Mexican Republic.</brief_summary>
	<brief_title>Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Men and women â‰¥15 years of age Diagnosis of chronic myeloid leukemia in any phase that used dasatinib at any time between January 2008 and November 2014 Have received dasatinib as part of their firstline or secondline treatment for at least 45 days Patients who received dasatinib as part of any clinical trial Patients who do not have complete data on the data collection sheet Patients who do not have medical records available at the moment of the data verification</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>